Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.
Total Funding: $161 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2C
Company Size: 26 to 50
Founded: 2017
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Icosavax
Director, Preclinical Development
Seattle, Washington
VP of Legal Affairs
Seattle, Washington
Manager, Quality Assurance
Seattle, Washington
Senior Research Associate, CMC
Seattle, Washington
Senior Program Manager
Seattle, Washington